
Sign up to save your podcasts
Or
In this week’s View, Dr. Eagle looks colchicine versus placebo in reducing major adverse cardiovascular (CV) events including CV death or myocardial infarction in patients with vascular disease. He then discusses insights from the Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) Transcatheter Valve Therapy (TVT) Registry in terms of direct oral anticoagulants (DOACs) versus warfarin after transcatheter aortic valve replacement (TAVR). Finally, Dr. Eagle explores the use of conduction system pacing (CSP) rather than biventricular pacing (BiVP) in achieving clinical and echocardiographic response.
Subscribe to Eagle’s Eye View
4.7
128128 ratings
In this week’s View, Dr. Eagle looks colchicine versus placebo in reducing major adverse cardiovascular (CV) events including CV death or myocardial infarction in patients with vascular disease. He then discusses insights from the Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) Transcatheter Valve Therapy (TVT) Registry in terms of direct oral anticoagulants (DOACs) versus warfarin after transcatheter aortic valve replacement (TAVR). Finally, Dr. Eagle explores the use of conduction system pacing (CSP) rather than biventricular pacing (BiVP) in achieving clinical and echocardiographic response.
Subscribe to Eagle’s Eye View
137 Listeners
319 Listeners
500 Listeners
171 Listeners
883 Listeners
30 Listeners
289 Listeners
3,339 Listeners
1,149 Listeners
59 Listeners
40 Listeners
190 Listeners
369 Listeners
432 Listeners
34 Listeners